BIOCRYST PHARMACEUTICALS INC (BCRX)

US09058V1035 - Common Stock

7.34  -0.01 (-0.14%)

BIOCRYST PHARMACEUTICALS INC

NASDAQ:BCRX (9/27/2023, 11:17:05 AM)

7.34

-0.01 (-0.14%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)08-03 2023-08-03/bmo
Earnings (Next)10-30 2023-10-30/bmo
Ins Owners1.47%
Inst Owners92.09%
Market Cap1.39B
Shares189.49M
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts80
IPO03-04 1994-03-04
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Growth Stock Screener

Find more growth stocks the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

BCRX Daily chart

Company Profile

BioCryst Pharmaceuticals, Inc. is a commercial-stage biotechnology company that discovers novel, oral, and small-molecule medicines. The company is headquartered in Durham, North Carolina and currently employs 531 full-time employees. The firm focuses on oral treatments for rare diseases, in which unmet medical needs exist and an enzyme plays the key role in the biological pathway of the disease. Its marketed products include oral, once-daily ORLADEYO for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), BCX9930, BCX9250, PERAMIFLU (peramivir injection), galidesivir, and early-stage discovery programs. BCX10013, is a potent and specific Factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. BCX9930 is an oral, potent, and selective small molecule inhibitor of Factor D. Galidesivir is a broad-spectrum antiviral that is active against viral families.

Company Info

BIOCRYST PHARMACEUTICALS INC

4505 Emperor Blvd Ste 200

Durham NORTH CAROLINA 27703

P: 19198591302.0

CEO: Jon P. Stonehouse

Employees: 531

Website: https://www.biocryst.com/

BCRX News

News Image9 days ago - BusinessInsiderBenzinga's Top Ratings Upgrades, Downgrades For September 18, 2023

News Image9 days ago - BioCryst Pharmaceuticals, Inc.INESSS Recommends Public Reimbursement for BioCryst’s ORLADEYO® (berotralstat) for the Prevention of Attacks for Hereditary Angioedema Patients in Québec

INTENDED FOR CANADIAN AUDIENCES ONLY...

News Image9 days ago - BioCryst Pharmaceuticals, Inc.L’INESSS recommande le remboursement public pour ORLADEYO® (bérotralstat) de BioCryst pour la prévention des crises chez les patients atteints d’angio-oedème héréditaire au Québec

DESTINÉ À UN AUDITOIRE CANADIEN SEULEMENT...

News Image22 days ago - BioCryst Pharmaceuticals, Inc.BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., Sept. 05, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted five newly-hired employees stock options to purchase an aggregate of 28,300 shares, and restricted stock units (RSUs) covering an aggregate of 19,900 shares, of BioCryst common stock. The options and RSUs were granted as of August 31, 2023, as inducements material to each employee entering into employment with BioCryst. The options and RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

News Imagea month ago - The Motley Fool3 Magnificent Growth Stocks to Buy on the Dip

These three biotech stocks are attractive buys right now.

News Imagea month ago - BioCryst Pharmaceuticals, Inc.BioCryst to Present at Upcoming Investor Conferences

RESEARCH TRIANGLE PARK, N.C., Aug. 23, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will...

BCRX Twits

Here you can normally see the latest stock twits on BCRX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example